A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 16 to 18
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Dementia
1,982 trials monitored
See 105 trials at risk
Alzheimer's Disease
1,255 trials monitored
See 68 trials at risk
The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.
Trial Details
NCT Number NCT07843459
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
Related terms Alzheimer Disease, Plaque, Amyloid
Enrollment 111 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov